Form 4: Guardant Health Director Tariq Musa Reports Stock Sale and Equity Awards Under 10b5-1 Plan

Guardant Health Director Tariq Musa reported the sale of 3,213 shares of common stock and the acquisition of 6,833 stock options and 4,203 restricted stock units, all executed under a Rule 10b5-1 trading plan.

Summary

• Director Tariq Musa of Guardant Health, Inc. reported transactions on June 18, 2025.
• He sold 3,213 shares of common stock at a price of $49.47 per share.
• He acquired 6,833 stock options with an exercise price of $50.57, which are set to vest on June 18, 2025, or the date of the next annual stockholders meeting, whichever is earlier, and expire on June 18, 2035.
• He also acquired 4,203 Restricted Stock Units (RSUs), which are set to vest on June 18, 2025, or the date of the next annual stockholders meeting, whichever is earlier.
• All reported transactions were conducted under a Rule 10b5-1(c) trading plan.
• Following these transactions, Mr. Musa beneficially owns 7,190 shares of common stock, 6,833 stock options, and 4,203 Restricted Stock Units.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. While there's a sale, it's offset by new equity awards and conducted under a 10b5-1 plan, which is generally viewed as a responsible way for insiders to manage their holdings.

Positives

• The acquisition of stock options and restricted stock units indicates continued equity incentive for the director, aligning his interests with shareholders.
• The transactions were conducted under a Rule 10b5-1 plan, suggesting pre-planned trades and reducing concerns about opportunistic insider trading.

Negatives

• A director selling shares, even under a 10b5-1 plan, can sometimes be perceived negatively by the market as it reduces their direct equity stake.

Future Outlook

The document does not provide any forward-looking statements or guidance beyond the vesting and expiration dates of the equity awards.

Industry Context

This Form 4 is a routine insider transaction report and does not provide information to analyze broader industry trends or competitors. It reflects an individual director's compensation and portfolio management.

Corporate Governance

Stakeholder Impact

• Shareholders: The sale of shares by a director could be perceived as a slight negative, but the simultaneous grant of new equity awards and the 10b5-1 plan mitigate this. Overall, it's a routine insider transaction.
• Employees, Customers, Suppliers, Creditors: No direct impact from this specific filing.

Next Steps

• The stock options and restricted stock units are scheduled to vest on June 18, 2025, or the date of the next annual stockholders meeting, whichever is earlier.

Key Dates

Recommendation

Keywords

Guardant Health, GH, Form 4, Insider Trading, Stock Sale, Stock Options, Restricted Stock Units, Equity Compensation, Director Transactions, 10b5-1 Plan